AbbVie — Full Portfolio
20 tracked investments · listed companies and verified rows first
Enanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need.
Biotech
Jay R. Luly(President, Director and Chief Executive Officer)Yat Sun Or(Chief Scientific Officer)Scott T. Rottinghaus(Chief Medical Officer)inMatthew P. Kowalsky(Chief Legal Officer and Corporate Secretary)Tara L. Kieffer(Chief Product Strategy Officer)inBrendan Luu(Chief Business Officer)in
Co-investorsSaints CapitalSofinnova Ventures
Exicure is a publicly-traded holding company that previously developed nucleic acid therapies and has since divested its historical biotechnology assets; it is now pursuing growth through acquisitions and partnerships, including a recent investment in GPCR Therapeutics USA, which is developing small molecule therapies for blood cancers and multiple myeloma.
BiotechSkokie, US
Chad A. Mirkin(Director)C. Shad Thaxton(Director)David A. Giljohann(Chief Executive Officer)inDavid S. Snyder(Chief Financial Officer)inPercy Van Crocker, Jr.(Vice President, Commercial Development)
BoardJay Venkatesan(Director)
Co-investorsAlumni VenturesInnovation EndeavorsPurple Arch VenturesRockPort Capital Partners
Light Horse Therapeutics is a drug discovery company applying scientific expertise and innovation to advance healthcare through collaborative development.
AI & Machine LearningBiotechMedical Devices
Co-investorsTaiho Ventures, LLCMubadala CapitalVersant Ventures
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsAtlas VentureDroia VenturesEcoR1 CapitalGV (Google Ventures)The Column GroupJJDC+3 more
Aquinnah Pharmaceuticals develops oral small-molecule therapeutics targeting pathologic biomolecular condensates, such as stress granules formed by RNA-binding proteins, to slow neurodegenerative diseases including ALS and Alzheimer's disease.
BiotechHealthtechLongevityCambridge, US
Benjamin Wolozin(CSO & Co-founder)inDr. Glenn Larsen(Co-founder, President and CEO)Dr. Ben Wolozin(Co-Founder and Chief Scientific Officer)
Co-investorsPfizer Venture Investments
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersDementia Discovery FundM VenturesNovartis Venture FundPfizer Venture InvestmentsRA Capital+6 more
Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases.
BiotechHealthtech
Co-investorsDementia Discovery FundEisai Innovation, Inc.McCarthy CapitalMRL Ventures FundSpringdale VenturesSV Health Investors+9 more
CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).
BiotechPhiladelphia, US
Steven Kelly(Executive Officer, Director)in
BoardMargarita Chavez(Director)inEran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)Regina Hodits(Director)in
Co-investorsAgent CapitalAju IB InvestmentAnzu PartnersGrazia Equity GmbHHealthCapLongview Innovation+4 more
Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.
BiotechHealthtechMilan, IT
Co-investorsSofinnova PartnersIndaco Venture PartnersRoche Venture FundJDRF T1D Fund
Leal Therapeutics is a company focused on CNS (central nervous system) disorders, drawing on academic and drug-development experience in neurology and neurodegenerative disease.
BiotechHealthtechMedical DevicesWorcester, US
Asa Abeliovich(CEO & Founder, Director)
Co-investorsOrbiMedSV Health InvestorsDementia Discovery FundNewpath Partners
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)in
Co-investorsARCH Venture PartnersJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Pfizer Venture InvestmentsSofinnova Partners+7 more
Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration.
BiotechHealthtechLongevity
Irene Griswold-Prenner(Founder & Chief Executive Officer)in
Co-investorsDementia Discovery FundMission BiocapitalSofinnova PartnersSV Health InvestorsMission Bay Capital
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
BoardMike Dial(Director)in
Co-investorsHatteras Venture PartnersIllumina VenturesM VenturesMC Healthcare VenturesPappas CapitalSV Health Investors+2 more
BiotechLexington, US
Victoria M. Richon(Executive Officer, Director)in
BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)
Co-investorsAvego BioScience CapitalOUP (Osage University Partners)Peregrine VenturesDeerfield Management CompanyJJDCNovartis Venture Fund+3 more
Stylus Medicine develops in vivo genetic medicines using engineered recombinases, with initial focus on creating CAR-T therapies delivered via lipid nanoparticles for oncology, autoimmune, and genetic diseases.
BiotechDigital HealthMedical Devices
Michael C. Bassik, Ph.D.(Scientific Founder)Emile Nuwaysir, Ph.D.(Chairman & Chief Executive Officer)inJason Fontenot, Ph.D.(Chief Scientific Officer)Ami Bhatt(Founder)Lacramioara Bintu(Founder)Michael Bassik(Founder)
Co-investorsBrainstorm VenturesCAL InnovationCalifornia Innovation FundKhosla VenturesNeva Sgr.RA Capital+1 more
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets.
AI & Machine LearningBiotechDeep TechDurham, US
Mark A. Hallen(Founder & CTO)inMarcel Frenkel(Founder & CEO)inDamien Petty(Director)inJia Wei Xu(Director)Bruce Donald, PhD(Founder & Chair SAB)
Co-investorsCape Fear BioCapitalDFJ DragonFundDraper AssociatesDuke Capital PartnersHatteras Venture PartnersSOSV+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Lodo TherapeuticsMagnolia NeurosciencesParagen BioPetra Pharma
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.






















































